Our discussion covers the background, pathophysiology and historic treatment options for patients with Thalassaemia. A new drug, LentiGlobin, has been used recently in clinical trials at UCLH. It involves genetically modifying autologous stem cells to produce sufficient Red blood cells, and takes away the need for blood transfusions.
Prof John Porter is a well-recognised consultant haematologist and expert on red cell haematology. He is Professor of Haematology at UCL and Head of the Red Cell Unit for UCLH and Whittington Hospitals, and has received a British Society of Haematology Gold Medal award.
